CIK 0001723128 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 3.0 B | 2.2 B | |
| Net income (USD) | 72.1 M | -270.6 M | |
| Diluted EPS (USD/shares) | 0.22 | -0.86 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-21 | 4 | FORM 4 | 2026-09-17 |
| 2026-09-14 | 4 | FORM 4 | 2026-09-11 |
| 2026-09-03 | S-3ASR | S-3ASR | |
| 2026-09-02 | 4 | FORM 4 | 2026-09-01 |
| 2026-08-25 | 4 | FORM 4 | 2026-08-21 |
| 2026-08-14 | 4 | FORM 4 | 2026-08-13 |
| 2026-08-13 | 4 | FORM 4 | 2026-08-12 |
| 2026-08-13 | 4 | FORM 4 | 2026-08-11 |
| 2026-08-13 | 4 | FORM 4 | 2026-08-11 |
| 2026-08-13 | 144 | 144 | |
| 2026-08-12 | 4 | FORM 4 | 2026-08-10 |
| 2026-08-12 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-08-12 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-08-12 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-08-12 | 4 | FORM 4 | 2026-08-10 |
| 2026-08-12 | 4 | FORM 4 | 2026-08-10 |
| 2026-08-12 | 4 | FORM 4 | 2026-08-10 |
| 2026-08-12 | 144 | 144 | |
| 2026-08-12 | 144 | 144 | |
| 2026-08-11 | 144 | 144 | |
| 2026-08-10 | 8-K | 8-K items 1.01,2.01,2.03,3.02,7.01,9.01 | 2026-08-10 |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-03 | 8-K | 8-K items 1.01 | 2026-08-03 |
| 2026-07-31 | 8-K | 8-K items 5.07 | 2026-07-31 |
| 2026-07-30 | DEFA14A | DEFA14A |
Forms on file (last 1,000): 4 309, 8-K 93, 3 37, 144 37, 10-Q 26, SC 13D/A 23, SC 13G/A 22, DEFA14A 17. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AMRX (0.002 USD), /gw/filings/filings?ticker=AMRX&form=8-K, /gw/filings/facts?ticker=AMRX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange